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ABSTRACT
Herpes zoster (HZ) is a common, painful
and debilitating disease caused by the reactivation
of latent varicella-zoster virus in ganglia. This
clinical event occurs more frequently in the
elderly and those who are immunocompromised.
The most common complication of HZ is
post-herpetic neuralgia (PHN) which is
responsible for the highest HZ-related burden of
illness and is challenging to treat. Due to the
important clinical and economic impact ofHZ and
PHN, and the suboptimal treatments that are
currently available, HZ vaccination is an
important approach to reduce the burden of
illness. Currently, one-dose, live-attenuated
vaccine is licensed in the United States and
Europe to prevent HZ and it is included in some
national immunization programs. The clinical
efficacy, safety and tolerability of the vaccine has
been demonstrated in two large phase III clinical
trials, involving more than 38,000 and 22,000
individualsaged C60and50–59 years, respectively.
This comprehensive review summarizes the
extensive ‘‘real-world’’ effectiveness and safety
data from both immunocompetent and
immunocompromised individuals. These data
confirm those from the clinical trials, supporting
the use of HZ vaccine in clinical practice and
provide evidence that the current
recommendations for immunocompromised
individuals should be revised.
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INTRODUCTION
The varicella-zoster virus (VZV) is a DNA virus
that belongs to the Herpesviridae family,
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subfamily Alphaherpesvirinae [1, 2]. After
primary infection with VZV, it remains
dormant in the dorsal root or cranial nerve
sensory ganglia. When reactivation occurs it
causes herpes zoster (HZ), also known as
shingles, usually characterized by a vesicular
eruption with severe pain in a single
dermatome segment [2–5].
The course of acute HZ episodes can be
complicated by post-herpetic neuralgia (PHN),
which is a painful and debilitating condition
defined as a chronic neuropathic resilient
pain that persists for 3 months or more from
the initial onset of the rash [6, 7]. The risk of
VZV reactivation increases with the decline of
cell-mediated immunity, particularly due to
the aging [3]. In addition, individuals who are
immunocompromised due by certain diseases,
such as hematologic malignancies and solid
cancers have an increased risk for a higher
incidence and severity of HZ and its
neurologic and ophthalmologic
complications and visceral dissemination
[8–16]. The risk of HZ and its complications
is also higher in patients with autoimmune
diseases, such as rheumatoid arthritis,
systemic lupus erythematosus, and Crohn’s
disease due to both the pathologic process
and to their immunosuppressive treatments
[17–24].
The annual incidence rates of HZ are similar
across countries, ranging from 3 to 5 per 1000
people in North America, Europe and
Asia–Pacific [25]. In all countries, HZ shows a
similar age-specific epidemiologic pattern, with
a steep increase in the incidence rate in those
aged 50 years or more, with up to 8–12 HZ cases
per 1000 persons in those aged 80 years or more
[25]. Nearly 50% of individuals aged 85 years or
more have experienced HZ [3].
The incidence of PHN also increases with
age, ranging between 5% and about 30% in the
adult population and between 25% and 50% in
adults aged 50 years or more [25].
Herpes zoster and PHN affect the
health-related quality of life and induce a
substantial economic burden [26]. PHN has
been reported to have an impact on physical,
psychological, functional and social aspects of
patients’ lives causing interference with daily
activities. HZ and PHN cannot be managed
satisfactorily with the currently available
treatments and severe cases require extensive
healthcare resources, particularly for specialist
consultations, diagnostic examinations, and
sometimes, hospitalization [27].
The live-attenuated HZ vaccine, Zostavax
(Merck Sharp & Dohme Corporation), was first
licensed by the American Food and Drug
Administration (FDA) in 2006 for the
prevention of HZ in adults aged C60 years [28].
In the same year, the Committee for Medicinal
Products for Human Use (CHMP) of the
European Medicines Agency (EMA) authorized
Zostavax for the prevention of both HZ and PHN
[29]. In March 2011, the FDA extended the
indication to include adults aged between 50
and 59 years [30]. Zostavax is currently the only
HZ vaccine approved for use in the United States
(US) and in Europe [29, 31]. After its licensure in
the US, the Advisory Committee on
Immunization Practices (ACIP) recommends
the use of Zostavax for prevention of HZ and its
complications among adults agedC60 years [32].
In this age group the vaccine is reimbursed by
private health insurance or through public
program.
Advisory Committee on Immunization
Practices also considered the use of HZ vaccine
among adults aged 50 through 59 years [30], but
up to date declines to recommend the vaccine
in this age group, citing shortages of Zostavax
and limited data on long-term protection in this
age group.
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In Europe, Zostavax has been recommended
and public funded in many countries, such as
United Kingdom, Greece, France and some
regions in Germany and Italy, according to
different immunization strategies. In Austria,
the HZ vaccine is recommended to adults aged
C50 years, but it is not public funded. The
results from two phase III clinical trials, which
lead to licensure of the vaccine, demonstrated
that Zostavax was safe, well-tolerated and
effective in preventing HZ and PHN in adults
aged C50 years [33, 34]. The efficacy of Zostavax
was reported to be 51.3% [95% confidence
interval (CI) 44.2; 57.6] and 66.5% (95% CI
47.5; 79.2) for preventing HZ and PHN,
respectively, in adults aged C60 years in
shingles prevention study (SPS;
ClinicalTrials.gov identifier: NCT00007501)
[32]. In the Zostavax Efficacy and Safety Trial
(ZEST; ClinicalTrials.gov identifier:
NCT00534248), its efficacy was 69.8% (95% CI
54.1; 80.6) for preventing HZ in adults aged
50–59 years [34].
Since the introduction of Zostavax in the US
immunization program nearly 10 years ago,
several effectiveness studies assessing the
efficacy of HZ vaccine in a ‘real-life’ setting
have been conducted in immunocompetent
and immunocompromised individuals. Here
we will summarize the results obtained in
these effectiveness studies. This article is based
on previously conducted studies, and does not
involve any new studies of human or animal




Since licensure, the effectiveness of HZ vaccine
has been assessed in three retrospective studies
in immunocompetent subjects in the US
(Table 1) [35–37]. One of these analyzed data
for 303,044 enrollees from the Kaiser
Permanente Southern California (KPSC) health
plan from January 2007 to December 2009 [35].
The results showed that the HZ vaccine
significantly reduced the risk of HZ [vaccine
effectiveness (VE): 55%; 95% CI 52%; 58%]; VE
was similar in all age groups and for individuals
with chronic diseases. The HZ vaccine also
reduced the risks of ophthalmic HZ (VE: 63%;
95% CI 39%; 77%) and HZ-related
hospitalizations (VE: 65%; 95% CI 49%; 76%).
Another large retrospective cohort study,
conducted over the same period (January 2007
to December 2009) included 766,330
immunocompetent and immunosuppressed
subjects aged C65 years enrolled in the
Medicare program [36]. VE against HZ,
adjusted for age, gender, race,
immunosuppression, low income, and
comorbidity, was 48% (95% CI 39%; 56%) for
all subjects and 51% (95% CI 41%, 59%) for
immunocompetent subjects. The study
reported VE against PHN at 30 and 90 days as
62% (95% CI 37%; 77%) and 59% (95% CI 21%;
79%), respectively. The third study assessed the
VE of the HZ vaccine among 176,078 vaccinated
and 528,234 unvaccinated KPSC enrollees. A
significant risk reduction for HZ was reported
for vaccinated subjects (VE: 51%; 95% CI 50%;
53%). The effectiveness was confirmed for all
age groups and in patients with chronic
diseases, but unlike the previous study, the VE
seemed to lower in those aged 60–69 years
compared with those aged C70 years [37].
Four smaller studies were conducted in
immunocompetent populations [38–41]. The
risk of recurrent HZ did not significantly differ
between vaccinated and unvaccinated
individuals in a matched cohort study among
elderly individuals agedC60 yearswhohadhad a
recent episodeofHZ [38].Another study reported
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that the overall risk of PHN was significantly
reduced in immunocompetent individuals aged
C60 years who had developed HZ, after having
received the HZ vaccine (VE: 41%; 95% CI 15%;
59%) [39]. Gender-specific analysis revealed that
the risk reduction for PHN was predominately
observed for women with no significant
difference for men. It was suggested that this
gender-related difference may reflect differences
in healthcare-seeking patterns but this requires
further investigation. The third study reported
that the VE of the HZ vaccine for HZ in
immunocompetent individuals was maintained
also when the vaccine was administered
concomitantly with polysaccharide
pneumococcal vaccine compared with
non-concomitant administration, with an
adjusted hazard ratio of 1.19 (95% CI 0.81;
1.74) [40]. Another matched case–control study
evaluated theVEof theHZvaccine forpreventing
other HZ-related outcomes, such as prodromal
symptoms and medically attended prodrome, as
well as HZ and PHN [41]. In SouthernMinnesota,
US, 266 case-patients with HZ aged C60 years
were matched with 362 controls from January 1,
2010 to October 12, 2011. The HZ vaccine
significantly prevented HZ (VE: 54%; 95% CI
32%; 69%), HZ-related prodromal symptoms
(VE: 58%; 95% CI 31%; 75%) and medically
attendedprodrome (VE: 70%; 95%CI33%; 87%).
TheHZvaccine also significantly reduced the risk
of PHN at 30 days after rash onset (VE: 61%; 95%




In clinical trials, the efficacy of HZ vaccine
decreased over time. Indeed, the findings from
short- and long-term persistence substudies,
conducted, respectively, among 7320 vaccine
and 6950 placebo recipients and 6867 vaccinees
enrolled in the SPS, demonstrated that vaccine
efficacy steadily declined after vaccination but
remained statistically significant forHZburden of
illness (BOI) through 10 years after vaccination.
On the other hand, vaccine efficacy for incidence
of HZ resulted statistically significant only until
8 years after immunization [42, 43].
Recently, Tseng and colleagues confirmed
the reduction of HZ vaccine efficacy in the
‘‘real-world’’ [37]. In the above-mentioned study
performed among KPSC members aged
C60 years vaccinated against HZ between
January 1, 2007 and December 31, 2014 and
528,234 unvaccinated subjects, they evaluated
the persistency of HZ VE over 8 years after
immunization. The VE in reducing the
incidence of HZ was reported to decline
gradually over time, with figures of 68.7%
(95% CI 66.3%; 70.9%) during year 1 and
49.5% (95% CI 45.7%; 53.1%) during year 2;
values ranging from 39.1% (95% CI
33.8–43.9%) to 32.9% (95% CI 23.1%; 41.5%)
during years 3–6; and values of 16.5% (95% CI
1.4%; 29.3%) during year 7. Eight years after
immunization, VE was 4.2% (95% CI -24.0%;
25.9%) and not statistically significant.
The reduction of protection against HZ and
PHN with increasing time post-vaccination has
been attributed to the declining levels of
vaccine-induced immunity to VZV with
increasing time after vaccination, as well as to
weakening host immune responses due to the




Although the licensed HZ live-attenuated
vaccine, Zostavax, has been shown to be safe
and effective in older adults, it is currently not
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recommended for use in patients with primary
and acquired immunodeficiency because of its
potential to trigger the development of HZ
within 4–6 weeks after vaccination
[15, 30, 44–48]. However, due to the high
incidence and severity of HZ and its
complications in patients with immunologic
disorders, vaccination could potentially offer
substantial benefits for these patients. Data
from ‘‘real-world’’ studies provide evidence that
the HZ vaccine could be effective and safe in
patients with immunologic disorders (Table 2)
[36, 49, 50]. In one study, HZ VE was assessed in
140,923 immunocompromised individuals
among whom 5531 were vaccinated [36]. The
incidence rates for HZ were higher in
unvaccinated immunocompromised
individuals compared with vaccinated
individuals and VE against HZ was estimated to
be 37% (95%CI 6%; 58%), providing support for
the effectiveness of HZ vaccine in these at risk
individuals [36]. A retrospective cohort study
assessedHZVE and safety in a large population of
463,541 Medicare beneficiaries aged C60 years
who had selected immune-mediated diseases,
using data from 2006 to 2009 (Table 2) [49].
Vaccinationwasnot associatedwith a short-term
increase in the risk for varicella or HZ and was
found to be associated with a decrease risk of HZ
with an estimatedVE of 39% (95%CI 29%; 48%).
In addition, they did not identify any safety
signals in vaccinated patients undergoing
biologic therapy within 42 days following
vaccination. These findings confirmed the
results of a previous smaller retrospective study
involving 44,115 younger patientswith the same
immune-mediated diseases enrolled in a private
healthcare insurance plan from 2006 to 2009. In
this study, the short-term HZ incidence rates
among the vaccinated and unvaccinated
individuals were similar and no safety issues
were reported [51].
In another study the incidence of HZ after
immunosuppressive chemotherapy was
compared in 4710 individuals aged C60 years
who had been vaccinated with HZ vaccine
before and in 16,766 individuals who had not
(Table 2) [50]. There were 91 (cumulative
incidence 3.3%) and 583 (cumulative
incidence 5.3%) HZ cases among vaccinated
and unvaccinated individual, respectively,
within the 30 months follow-up period,
resulting in an adjusted VE of 42% (95% CI
27%; 54%). This VE in immunocompromised
patients was comparable to that reported for
immunocompetent individuals evaluated in
their previous study, 45% (95% CI 42%; 54%),
suggesting that offering HZ vaccination to
patients undergoing chemotherapy in a timely
manner could offer substantial benefits [35].
REAL-WORLD SAFETY OF HZ
VACCINE
Since its licensure, the safety profile of the HZ
vaccine has been investigated in large studies
conducted in ‘‘real-world’’ settings. The results
have been generally consistent with those
reported in clinical trials, with no safety
concerns detected, in both the general
population and in certain patient groups with
immune-mediated conditions. In one study,
using data from the Vaccine Safety Datalink
Project it was reported that the HZ vaccine is
safe and well-tolerated in subjects aged
C50 years, confirming pre-licensure results
[52]. In addition, in this ‘‘real-world’’ setting,
no increased risks for cerebrovascular,
cardiovascular or neurological events were
observed [52]. The optimal safety profile was
also established: results from a large cohort
study in about 29,000 vaccinated individuals
aged C60 years enrolled in the Kaiser
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Permanente Northern California reported no
short-term or long-term safety issues [53].
Recently, the results from a matched
case–control study of events reported in the
US Vaccine Adverse Event Reporting System
(VAERS) demonstrated no significantly
increased risk of exacerbation or induction of
severe autoimmune diseases, including
Guillain–Barre syndrome, multiple sclerosis,
optic neuritis, systemic lupus erythematosus,
thrombocytopenia or vasculitis, after
vaccination [54]. However, HZ vaccine
recipients were significantly more likely to
develop alopecia or arthritis than recipients of
tetanus toxoid-containing vaccines.
The HZ vaccine has been reported to be safe in
two studies conducted among patients
undergoing immunosuppressive treatments. In
particular, no adverse reactions were reported in
62 patients with hematologic malignancy
following the administration of the HZ vaccine
[55]. Another study, conducted using data from
14,554adults agedC18 years in theVaccineSafety
Datalink Project, reported amodest increased risk
of HZ within the 42 days after immunization in
current immunosuppressantdrugusers compared
with previous immunosuppressant drugs users,
thus supporting the current recommendations to
withhold immunosuppressant treatment for
4 weeks before HZ vaccine administration [56].
Indeed, the study authors attributed this
increased risk to the reactivation of VZV latent
infection rather than vaccine viral strain
dissemination.
CONCLUSIONS
This comprehensive review has summarized
available evidence for HZ VE and safety from
studies with different designs, conducted in
different populations in ‘‘real-world’’ settings.
This evidence confirms the promising impact of
the HZ vaccine on the incidence of HZ and PHN
observed in the pre-licensure clinical trials in
‘‘real-world’’ settings. In particular, the vaccine’s
good safety and tolerability profiles have been
confirmed in all available studies. Robust data
show that the HZ vaccine can prevent HZ and
PHN in immunocompetent individuals although
the VE appears to decline with increasing age and
time after vaccine administration, suggesting the
need for a booster dose which is currently under
discussion. Additionally, a single study has
provided some evidence that the HZ vaccine
may also be effective for the reduction of
HZ-related hospitalizations and ophthalmic HZ.
Nevertheless, more studies are needed to confirm
these results.AlthoughHZvaccineuse is currently
contraindicated in immunocompromised
individuals, available evidence suggests there
may be a potential benefit of HZ vaccine in
immunosuppressed patients and in individuals
with selected immune-mediated diseases in this
group with a good safety profile. Thus, there is
evidence that the current recommendations in
these populations should be reconsidered and
revised. Overall, the ‘‘real-world’’ data
summarized here provide a reassuring picture of
the HZ vaccine performance during routine
clinical practice.
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